Samsung Bioepis Selected as 'Asia-Pacific Company of the Year'

Samsung Bioepis headquarters building exterior. [Photo by Samsung Bioepis]

[Asia Economy Reporter Lee Gwanju] Samsung Bioepis announced on the 3rd that it was selected as the 'Company of the Year, Asia-Pacific' at the 'Global Generics & Biosimilars Awards 2022' held in Frankfurt, Germany.

The 'Global Generics & Biosimilars Awards' is an annual awards event hosted by the pharmaceutical industry information service provider Citeline, recognizing companies worldwide in the generics and biosimilars industry that have achieved notable accomplishments in management performance, innovation, and social contribution over the past year.

Samsung Bioepis was recognized as a leading company in the biosimilars industry after winning the Biosimilar Initiative of the Year award in 2020 and receiving the award again after two years. In particular, the approval of the Lucentis biosimilar 'SB11' by the U.S. Food and Drug Administration (FDA) last year and its launch in the U.S. in June this year as the first Lucentis biosimilar were highly praised.

Go Hanseung, President of Samsung Bioepis, said, "It is an honor to be recognized once again as a leading company in the biosimilars industry, and I believe this is the result of our continuous efforts to realize our vision of providing high-quality biopharmaceuticals to more patients." He added, "We will continue to strive to improve patients' quality of life through innovative technologies."

Samsung Bioepis currently has a pipeline of 10 biosimilars, with six products being sold in the global market. In particular, three autoimmune disease treatments have been prescribed to more than 256,000 patients in Europe alone, contributing to medical cost savings of over 2.6 billion euros across Europe.

This content was produced with the assistance of AI translation services.